摘要
目的:探讨康柏西普联合全视网膜激光光凝(PRP)治疗糖尿病视网膜病变(DR)合并Ⅰ期~Ⅱ期新生血管性青光眼(NVG)的疗效。方法:选取60例(60眼)DR合并Ⅰ期~Ⅱ期NVG患者,随机分为观察组和对照组,每组30例(30眼)。对照组给予PRP治疗,观察组给予康柏西普联合PRP治疗。比较两组新生血管分级、眼压及logMAR最佳矫正视力(BCVA)。结果:治疗后,观察组房角新生血管分级较对照组显著改善,差异有统计学意义(P<0.05);观察组虹膜新生血管分级较对照组显著改善,差异有统计学意义(P<0.05);观察组眼压及logMAR BCVA较对照组显著降低,差异有统计学意义(P<0.05)。结论:康柏西普联合PRP治疗DR合并Ⅰ期~Ⅱ期NVG,可有效减少新生血管数量,降低眼压,改善视力,其效果优于单纯PRP治疗。
Objective To evaluate the effect of conbercept combined with panretinal photocoagulation(PRP)on diabetic retinopathy(DR)with I~Ⅱstage neovascular glaucoma(NVG).Method 60 DR patients(60 eyes)withⅠ~Ⅱstage NVG were divided into observation group and control group,30 cases(30 eyes)with each group.The control group was given to PRP,and the observation group was given to conbercept combined with PRP.The neovascularization grading,intraocular pressure and logMAR BCVA were compared between the two groups.Results After treatment,the neovascularization grading of anterior chamber angle in observation group was significantly improved compared with control group(P<0.05).The neovascularization grading of iris in observation group was significantly improved compared with control group(P<0.05).The intraocular pressure and logMAR BCVA of observation group was significantly lower than control group(P<0.05).Conclusion Conbercept combined with PRP treatment for DR withⅠ~Ⅱstage NVG,can effectively reduce the number of new blood vessels,reduce intraocular pressure,improve eyesight,its effect is better than that of pure PRP therapy.
作者
覃柳
QIN Liu(Department of Ophthalmology,the first people's Hospital of Nanning,Guangxi,Nanning 530000,China)
出处
《吉林医学》
CAS
2022年第2期418-420,共3页
Jilin Medical Journal
